ArticleFrontiers in public health2026
Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and application of the vaccine reporting quality score to evaluate the vaccine adverse event reporting system.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: While vaccination is a vital and cost-effective public health tool, a small fraction of recipients experience serious adverse events (SAEs) that impose a profound clinical and systemic burden. Identifying the specific factors that predispose an individual to an SAE remains complex due to limitations in existing literature. This study analyzes SAE following immunization in the US population and identifies associated factors. Methods: We analyzed a national cross-section of 50,655 reports submitted to the Vaccine Adverse Event Reporting System (VAERS) throughout 2025. Data were categorized into five domains: demographic characteristics, clinical features, medical history, vaccine variables, and patient outcomes. A multivariable logistic regression model was employed to identify factors associated with reporting SAEs. Results: Of the 50,655 AEFIs reported (median age: 40 years), 9.58% were classified as SAEs. Multivariable analysis identified significant demographic and clinical factors associated with SAE reporting, including advanced age (≥65 years, aOR: 1.73), male sex (aOR for females: 0.72), longer onset times (aOR: 1.06), administration facilities (military, aOR: 1.76; private facilities, aOR: 1.39), and systemic symptoms (aOR: 1.72), while local symptoms were highly protective (aOR: 0.35). Patient history variables, such as current illness (aOR: 1.51) and medical history (aOR: 1.24), were associated with increased odds of SAE reporting, while prior reactions were protective (aOR: 0.77). Regarding vaccine characteristics, mRNA platforms (Pfizer/Wyeth aOR: 1.65), second doses (aOR: 1.33), non-intramuscular administration routes (oral aOR: 2.85; subcutaneous aOR: 1.51), and right-arm injections (aOR: 1.24) were all associated with higher odds of SAEs. Conclusion: SAE reporting is driven by a complex intersection of demographic, clinical, and vaccine-related characteristics. These findings carry significant clinical and public health implications, highlighting the need for enhanced screening and proactive monitoring of high-risk populations to optimize global vaccine safety protocols. Future studies should integrate passive reporting with active surveillance to optimize vaccine safety protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.